Your essential biotech, medtech, and pharma recap — no noise, just what matters.

See the full searchable ASCO 2026 agenda — every Plenary readout, filterable by tumor track → biomednexus.com/asco-2026

⚡ Executive Takeaway

ASCO 2026 was the most consequential oncology meeting in years. The plenary sessions set three new treatment standards in a single afternoon (we covered these in detail yesterday). But the oral abstract sessions were nearly as important. The KEYNOTE-B15/EV-304 data in bladder cancer showed that combining an ADC (enfortumab vedotin) with a checkpoint inhibitor (Keytruda) before and after surgery produced pathologic complete responses in more than half of patients, nearly doubling the chemotherapy rate. This is the ADC-plus-IO combination thesis validated in yet another tumor type. Kelonia's in vivo CAR-T presentation at ASCO gave the first detailed look at the data that led Lilly to pay $3.2B for a company that had raised $60M total. Fierce Biotech said the data helped "justify" the price tag. And J&J's CHRYSALIS-2 update showed 41-month median OS with Rybrevant plus Lazcluze in atypical EGFR NSCLC, a population with historically poor outcomes, further solidifying J&J's lung cancer franchise. Outside ASCO, Apogee locked in $1.3B from Blackstone, one of the largest non-dilutive biotech financings of the year, to push zumilokibart through pivotal development in atopic dermatitis. And Hengrui presented 90+ studies, a reminder that the China-to-West pipeline we have tracked all year is producing data at scale. 👉 Read Full Analysis

🔮 What To Watch

🔬 ASCO Wrap-Up: The Data That Mattered Beyond the Plenary

Bladder Cancer: EV-304 ADC + IO Combination Produces 55.8% Complete Response MRK | PFE

The Phase 3 KEYNOTE-B15/EV-304 trial showed that enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) produced a 55.8% pathologic complete response rate in perioperative muscle-invasive bladder cancer, compared with 32.5% for gemcitabine/cisplatin chemotherapy (estimated difference 23.4%, p<0.0001). This validates the ADC-plus-checkpoint-inhibitor combination approach in yet another tumor type, following similar successes in breast cancer (Enhertu) and lung cancer (sac-TMT + Keytruda). The result positions Padcev plus Keytruda as a potential new perioperative standard.

Kelonia In Vivo CAR-T Data Justify Lilly's $3.2B Investment LLY

Fierce Biotech reported that Kelonia "shared the largest slice of data yet for its in vivo CAR-T, helping to justify the $3.2 billion price tag Lilly recently paid for the biotech." The data from the KLN-1010 program (lentiviral in vivo anti-BCMA CAR-T for multiple myeloma) were presented at ASCO, giving the oncology community its first detailed look at the clinical evidence behind Lilly's biggest cell therapy acquisition.

J&J Rybrevant + Lazcluze: 41-Month OS in Atypical EGFR NSCLC JNJ

Updated CHRYSALIS-2 data showed amivantamab (Rybrevant) plus lazertinib (Lazcluze) achieved a median OS of 41.0 months at 31.3 months of follow-up in first-line atypical EGFR-mutated advanced NSCLC. Fifty-five percent of patients were alive at three years. Investigators noted this regimen has now demonstrated "substantial survival benefit in both classical and atypical EGFR-mutated advanced NSCLC."

Hengrui Presented 90+ Studies

Hengrui Pharmaceuticals presented more than 90 oncology studies at ASCO 2026, the largest ASCO presence by any Chinese pharma company. The data spanned multiple tumor types and modalities, reinforcing Hengrui's position as a leading source of clinical-stage oncology assets for Western licensing partners (BMS signed a $15.2B deal with Hengrui in May, Lilly partnered via Kailera).

🏢 Corporate & Business Developments

Apogee Locks In $1.3B from Blackstone for Zumilokibart APGE

Apogee Therapeutics entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3B in flexible, non-dilutive capital to support development and potential commercialization of zumilokibart in atopic dermatitis, according to The Pharma Letter. Zumilokibart is an anti-OX40L antibody in Phase 2/3 development. The Blackstone financing is one of the largest non-dilutive biotech deals of 2026 and gives Apogee a runway to pursue pivotal development and potential launch without additional equity dilution.

📊 ASCO 2026: The Final Scorecard

ASCO 2026 Themes:

📅 The Week Ahead

👉 Read Full Analysis

1. ADCs are the new backbone of oncology treatment. Three ADC datasets at ASCO (EV-304, sac-TMT + Keytruda, Kelonia in vivo CAR-T adjacent data) join two recent approvals (Enhertu early breast cancer, Datroway 1L TNBC) to establish ADCs as the fastest-growing modality in oncology. Every major pharma company is now invested in ADCs: Gilead ($15B across Arcellx/Ouro/Tubulis), Merck (Kelun-Biotech sac-TMT), Lilly (CrossBridge), AstraZeneca/Daiichi Sankyo (Enhertu, Datroway), and J&J (EV-304). The next wave of ADC filings will come in 2026 and 2027 across lung, bladder, endometrial, and gastric cancers.

2. RAS inhibitors created a new GI oncology franchise. Daraxonrasib's RASolute 302 data (OS HR 0.40, PFS HR 0.49) established the first targeted therapy with a survival benefit in pancreatic cancer. Revolution's CNPV filing is imminent. The company already has first-line combination data (58% ORR at AACR) and a next-generation catalytic inhibitor (RM-055). AbbVie/Kestrel, Erasca, and others are pursuing KRAS, but Revolution has a substantial lead.

3. Bispecific antibodies produced their first OS data. Ivonescimab's HARMONi-6 OS result (HR 0.66) is the first time a bispecific antibody has demonstrated an overall survival advantage over a PD-1 inhibitor in a Phase 3 trial. The U.S. path is complicated (Chinese-only data, Summit Therapeutics as partner), but the mechanistic validation is clear.

4. In vivo CAR-T moved to the clinic. Kelonia's ASCO presentation gave the oncology community its first detailed look at lentiviral in vivo CAR-T data. Lilly paid $3.2B. The data apparently justified the price. If in vivo CAR-T works at scale, it replaces the costly, time-consuming ex vivo manufacturing process and makes cell therapy accessible to a far larger patient population.

5. China's oncology pipeline is now global. Hengrui presented 90+ studies. Akeso got the first Chinese plenary in 61 years. Kelun-Biotech's sac-TMT produced two Phase 3 wins for Merck. The COINS Act debate will intensify, but the data quality from Chinese biotech is now undeniable.

💊 What Comes Next

The next 90 days will determine the commercial trajectory of several ASCO datasets:

🎯 Catalyst Calendar: June 2026 Forward

👉 Visit The Pro Hub

Limited ASCO-week sponsorship slots available (May 29 - June 2). Reach 65,000+ professionals during the biggest oncology event of the year. Learn more →

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →